Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

September 1, 2010 Approval Letter - Rotarix

Public Health Service
Food and Drug Administration
Rockville, MD 20852-1448

Our STN: BL 125265/287

GlaxoSmithKline Biologicals Attention: Benedicte T. Dupasquier
2301 Renaissance Boulevard
P.O. Box 61540
King of Prussia, PA 19406-2772

Dear Ms. Dupasquier:

We have approved your request to supplement your biologics license application for Human Rotavirus Vaccine, Live, Oral (Rotarix®), to update the package insert and patient information labeling to reflect the presence of Porcine Circovirus Type-1 in the vaccine.

We will include information contained in the above-referenced supplement in your biologics license application file.

Sincerely yours,

Wellington Sun, M.D.
Division of Vaccines and
Related Products Applications
Office of Vaccines
Research and Review
Center for Biologics
Evaluation and Research

Attachment: Approved Final Draft Labeling

Resources for You

Page Last Updated: 09/08/2010
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English